Get started
Author

Takeshi Kadokura

Observed names: T. Kadokura, 門倉健
ORCID: 0000-0001-5360-6004
Observed ORCID: 0000-0001-5360-6004
OpenAlex ID: A5081633655
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
2019 · Shunji Takahashi, Motohide Uemura, et al. · Investigational New Drugs · 81
PDF
Renal Glucose Handling
2013 · Ele Ferrannini, Stephan A. Veltkamp, et al. · Diabetes Care · 81
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
2020 · Angela Joubert James, Catherine C. Smith, et al. · Clinical Pharmacokinetics · 73
PDF
Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
2011 · Stephan A. Veltkamp, Takeshi Kadokura, et al. · Clinical Drug Investigation · 55
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
2024 · Mei Tang, Amit Garg, et al. · Clinical Pharmacokinetics · 46
PDF
Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects
2011 · Takeshi Kadokura, Masako Saito, et al. · Diabetology International · 37
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
2014 · Takeshi Kadokura, Noriko Akiyama, et al. · Diabetes Research and Clinical Practice · 36
Discovery of N -[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor
2011 · Fukushi Hirayama, Hiroyuki Koshio, et al. · Journal of Medicinal Chemistry · 35
Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
2014 · Takeshi Kadokura, Wenhui Zhang, et al. · Clinical Pharmacokinetics · 32
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
2012 · R. A. Smulders, W. Zhang, et al. · Diabetes Obesity and Metabolism · 29
The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
2013 · Wenhui Zhang, Walter J. J. Krauwinkel, et al. · Clinical Drug Investigation · 26
Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus
2012 · Stephan A. Veltkamp, Jan van Dijk, et al. · Clinical Therapeutics · 22
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
2024 · Jianxiang Wang, Bin Jiang, et al. · Leukemia · 19
PDF
YM150, An Oral Direct Inhibitor of Factor Xa, Demonstrated a Predictable and Dose-Proportional Pharmacokinetic/Pharmacodynamic Profile After Single and Multiple Dosing: Results From Three Studies
2010 · Dorien Groenendaal– van de Meent, Marten Heeringa, et al. · Blood · 16
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
2013 · Takeshi Kadokura, Makoto Kashiwa, et al. · Biopharmaceutics & Drug Disposition · 12
The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects
2008 · Takeshi Kadokura, Martin den Adel, et al. · European Journal of Clinical Pharmacology · 10
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P‐glycoprotein and CYP3A4
2012 · Dorien Groenendaal, Gregory Strabach, et al. · British Journal of Clinical Pharmacology · 9
PDF
Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
2021 · Jianxiang Wang, Bin Jiang, et al. · Blood · 8
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
2019 · Masako Saito, Atsunori Kaibara, et al. · British Journal of Clinical Pharmacology · 8
PDF
The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects
2008 · Takeshi Kadokura, Martin den Adel, et al. · European Journal of Clinical Pharmacology · 8
Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors.
2022 · Mei Tang, Amit Garg, et al. · Journal of Clinical Oncology · 7
Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study
2015 · Catherine C. Smith, Mark J. Levis, et al. · Blood · 7
Ipragliflozin Does Not Prolong QTc Interval in Healthy Male and Female Subjects: A Phase I Study
2013 · Wenhui Zhang, Ronald Smulders, et al. · Clinical Therapeutics · 7
Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
2016 · Catherine Choy Smith, Mark J. Levis, et al. · Journal of Clinical Oncology · 6
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin
2013 · Takeshi Kadokura, Dorien Groenendaal, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 6
Works count: 38
Citation count: 688
H-index: 14
I10-index: 16
Year
Topic
Type